Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Antisense oligonucleotide reduction of human alpha-synuclein accumulation in dopamine and serotonin neurons prevents early dysfunctions in a mouse model of Parkinson's disease

  • Alarcón-Arís, Diana
  • Ruiz-Bronchal, Esther
  • Montefeltro, Andrés
  • Artigas, Francesc
  • Bortolozzi, Analía
Trabajo presentado en el Alpha-synuclein & Parkinson’s disease Conference: Lessons from the past 20 years, celebrado en la Universitat de Barcelona los días 11 y 12 de mayo de 2017, Pathological changes in end-state of Parkinson’s disease (PD) are well characterized. However, there is an urgent need to identify early functional changes to develop new therapeutic strategies stopping the development of the illness. α-Synuclein is a protein accumulating in the brain of PD patients. We generated a mouse model overexpressing wild-type human-α-synuclein in dopamine-DA or serotonin-5-HT neurons of substantia nigra-(SNc) and raphe nuclei-(RN), respectively. These mice showed increased human-α-synuclein mRNA levels in the ipsilateral SNc and RN, without loss tyrosine hydroxylase-(TH)-positive or tryptophan hydroxylase- (TPH2)-positive neurons. Moreover, reduced DA and 5-HT release with development of αsynuclein-positive axonal swelling in striatum were found in these mice. In addition, AAV5 mice exhibited motor deficits at 8 weeks post-infection into SNc and depressive-like behaviors at 4 weeks post-infection into RN. Here, we evaluated whether reducing human-α-synuclein expression in the mesencephalic nuclei prevented early dysfunctions in the AAV5 model. We used a conjugated antisense oligonucleotide targeting intracellular human-α-synuclein (ASO1337) selectively in DA and 5-HT neurons. Mice overexpressing human-α-synuclein in the SNc/VTA or RN were treated intracerebroventricularly with vehicle, nonsense ASO sequence (ASO1227) or ASO1337 (30 or 100μg/day) during 28 days using osmotic minipumps implanted subcutaneously. ASO1337 reduced dose-dependent the human-α-synuclein mRNA levels (ASO1337 30μg/day: 60,21%±15.93; ASO1337 100μ/day: 46.71%±8.63, respect vehicle) whereas endogenous α-synuclein expression remained unaltered. Immunohistochemistry shows the reduction of human-α-synuclein protein density (vehicle: 245,56%±5.32: ASO1337 30μg/day: 177.7%±7.65; ASO1337 100μ/day: 173%±2.93, respect contralateral side). Furthermore, recovery of striatal DA release was achieved by reduction of human-α-synuclein expression in SNc/VTA. Our study indicated that the reduction of intracellular α-synuclein accumulation selectively in DA and 5-HT neurons using ASO molecules represents an optimal PD therapy., Spanish Ministry of Economy and Competitiveness, INNPACTO Subprogram IPT2012-1208-300000 and Retos-Colaboración Subprogram RTC-2014-2812-1; Instituto de Salud Carlos III PI13/01390 co-financed by the European Regional Development Fund “A way to build Europe”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Short -and long- term memory impairment in mice overexpressing alpha -and gamma- synuclein in the dopamine neurons. Implication in Parkinson' disease

  • Pavia-Collado, Rubén
  • Alarcón-Arís, Diana
  • Ruiz-Bronchal, Esther
  • Artigas, Francesc
  • Bortolozzi, Analía
Trabajo presentado en el Neuroscience 2017, celebrado en Washington del 11 al 15 de noviembre de 2017, Idiopathic Parkinson’s disease (PD) is characterized by progressive brain pathology affecting multiple neurotransmitter systems, leading to a diverse profile of autonomic, motor, cognitive and psychiatric dysfunctions. Multiple convergent lines of evidence implicate the aggregation and accumulation of α-synuclein in the PD pathogenesis. Moreover, post-translational changes of γ-synuclein increase the α-synuclein aggregation. α- and γ-Synuclein are members of the synuclein family of small cytoplasmatic neuron-specific proteins, and have been suggested to modulate the function of monoamine transporters (DAT, SERT). We previously reported that α-synuclein knockdown mice showed increased extracellular DA and 5-HT levels- compard to control mice- in caudate-putamen (CPu) and medial prefrontal cortex (mPFC) after DAT or SERT blockade with nomifensine or citalopram, respectively (Alarcón-Arís et al., in review). Given the role of monoamine neurotransmission in cognitive processes, in the present study we assessed the effects of over-expressing α- and γ-synuclein in DA neurons on short- and long-term spatial memory. We generated a mouse model overexpressing the human wild-type α- or γ-synuclein in DA neurons from the substantia nigra compacta (SNc) and ventral tegmental area (VTA) using an adeno-associated virus type-5 (AAV5)-α-synuclein or AAV10-γ-synuclein, unilaterally injected in SNc/VTA. AAV5-α-synuclein mice showed increased human α-synuclein mRNA levels in the ipsilateral SN over time, reaching a 278% of sham mice at 8 weeks post-infection. Similarly, AAV10-γ-synuclein mice reached to a maximal of 250% of sham mice. Overexpression of α- or γ-synuclein led to lower extracellular DA levels in CPu and mPFC compared to sham mice after local veratridine (50μM) or nomifensine (1-10-50μM) administration at 4-week post-infection. Moreover, overexpression of α- or γ-synuclein led to the impairment of working memory in mice, as revealed by passive avoidance and novel object recognition tests at 4-8 weeks post-infusion. Likewise, these mice showed deficits in the spatial learning using the Morris water maze. These non-motor symptoms appeared earlier than motor deficits assessed by the cylinder test and rotarod. Overall, these findings indicate that that 1) α- and γ-synuclein are directly involved in the regulation of cognitive functions, likely through changes in monoamine function, and 2) overexpression of α- or γ-synuclein in DA neurons mimics the temporal progression of clinical symptoms in PD, with early cognitive deficits appearing before motor symptoms., Peer reviewed